<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02694601</url>
  </required_header>
  <id_info>
    <org_study_id>2014-441</org_study_id>
    <nct_id>NCT02694601</nct_id>
  </id_info>
  <brief_title>Ketone Production With Acute Caffeine Intake</brief_title>
  <official_title>Stimulate the Ketogenesis by Using a Caffeine Supplement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the effect of a caffeine supplement on the stimulation of lipolysis and the
      production of ketones in healthy adults (N=10).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to evaluate the effect of a caffeine supplement on the stimulation of
      lipolysis and the production of ketones in healthy adults (N=10). Two different doses of
      caffeine (2.5 mg/kg of BW and 5 mg/kg of BW) are compared. All the participants have to
      follow three sequential visits of four hours each, which included a breakfast with one of the
      doses (2.5 or 5 mg/kg) of the caffeine supplement or without any supplement (baseline) and
      repeated blood sampling in order to evaluate ketone concentrations.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Acetoacetate Concentrations</measure>
    <time_frame>4 hours</time_frame>
    <description>Plasma acetoacetate (µmol/L) measured over a 4 hour period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Beta-hydroxybutyrate Concentrations</measure>
    <time_frame>4 hours</time_frame>
    <description>Plasma beta-hydroxybutyrate (µmol/L) measured over a 4 hour period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Glucose Concentrations</measure>
    <time_frame>4 hours</time_frame>
    <description>Plasma glucose (mmol/L) measured over a 4 hour period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Cholesterol Concentrations</measure>
    <time_frame>4 hours</time_frame>
    <description>Plasma cholesterol (mmol/L) measured over a 4 hour period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Triglyceride Concentrations</measure>
    <time_frame>4 hours</time_frame>
    <description>Plasma triglycerides (mmol/L) measured over a 4 hour period.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy Adults</condition>
  <arm_group>
    <arm_group_label>Ketonemia following caffeine intake</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants have to follow three sequential visits of four hours each, which included a breakfast with one of the doses (2.5 or 5 mg/kg) of the caffeine supplement or without any supplement (baseline) and repeated blood sampling in order to evaluate ketone concentrations.
Intervention 1: Control; no caffeine intake Intervention 2: Caffeine low dose (2.5 mg/kg of BW) Intervention 3: Caffeine high dose (5.0 mg/kg of MW)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>4-hour visit with no caffeine is given during a standardize breakfast follow by repeated blood sampling.</description>
    <arm_group_label>Ketonemia following caffeine intake</arm_group_label>
    <other_name>CTL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Caffeine low dose</intervention_name>
    <description>4-hour visit with a dose of 2.5 mg/kg of caffeine is given during a standardize breakfast follow by repeated blood sampling.</description>
    <arm_group_label>Ketonemia following caffeine intake</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Caffeine high dose</intervention_name>
    <description>4-hour visit with a dose of 5 mg/kg of caffeine is given during a standardize breakfast follow by repeated blood sampling.</description>
    <arm_group_label>Ketonemia following caffeine intake</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults

          -  18 years old and over

        Exclusion Criteria:

          -  Drinking more than 300 mg of caffeine per day

          -  Diabetes or prediabetes

          -  Abnormal liver and kidney function

          -  Uncontrolled dyslipidemia, blood pressure

          -  Use of drugs known to influence the metabolism of lipids and carbohydrates (steroid,
             beta-blockers, diuretics, insulin sensitizer, etc.)

          -  Severe inflammation or infection

          -  Pregnancy

          -  Smoking
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Cunnane, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Centre on Aging - CSSS-IUGS - CIUSSS de l'Estrie - CHUS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Centre on Aging (CSSS-IUGS - CIUSSS de l'Estrie - CHUS)</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H4C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>February 9, 2016</study_first_submitted>
  <study_first_submitted_qc>February 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2016</study_first_posted>
  <results_first_submitted>September 12, 2017</results_first_submitted>
  <results_first_submitted_qc>September 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 15, 2018</results_first_posted>
  <last_update_submitted>February 8, 2019</last_update_submitted>
  <last_update_submitted_qc>February 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ketones</keyword>
  <keyword>Glucose</keyword>
  <keyword>Caffeine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caffeine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ketonemia Following Caffeine Intake</title>
          <description>Participants have to follow three sequential visits of four hours each, which included a breakfast with one of the doses (2.5 or 5 mg/kg) of the caffeine supplement or without any supplement (baseline) and repeated blood sampling in order to evaluate ketone concentrations.
Intervention 1: Control; no caffeine intake Intervention 2: Caffeine low dose (2.5 mg/kg of BW) Intervention 3: Caffeine high dose (5 mg/kg of BW)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketonemia Following Caffeine Intake</title>
          <description>Participants have to follow three sequential visits of four hours each, which included a breakfast with one of the doses (2.5 or 5 mg/kg) of the caffeine supplement or without any supplement (baseline) and repeated blood sampling in order to evaluate ketone concentrations.
Intervention 1: Control; no caffeine intake Intervention 2: Caffeine low dose (2.5 mg/kg of BW) Intervention 3: Caffeine high dose (5 mg/kg of BW)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasma Acetoacetate Concentrations</title>
        <description>Plasma acetoacetate (µmol/L) measured over a 4 hour period.</description>
        <time_frame>4 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketonemia Following Caffeine Intake</title>
            <description>Participants have to follow three sequential visits of four hours each, which included a breakfast with one of the doses (2.5 or 5 mg/kg) of the caffeine supplement or without any supplement (baseline) and repeated blood sampling in order to evaluate ketone concentrations.
Intervention 1: Control; no caffeine intake Intervention 2: Caffeine low dose (2.5 mg/kg of BW) Intervention 3: Caffeine high dose (5 mg/kg of BW)</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Acetoacetate Concentrations</title>
          <description>Plasma acetoacetate (µmol/L) measured over a 4 hour period.</description>
          <units>µmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CTL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.06" spread="3.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caffeine low dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.99" spread="5.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caffeine high dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.10" spread="8.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Beta-hydroxybutyrate Concentrations</title>
        <description>Plasma beta-hydroxybutyrate (µmol/L) measured over a 4 hour period.</description>
        <time_frame>4 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketonemia Following Caffeine Intake</title>
            <description>Participants have to follow three sequential visits of four hours each, which included a breakfast with one of the doses (2.5 or 5 mg/kg) of the caffeine supplement or without any supplement (baseline) and repeated blood sampling in order to evaluate ketone concentrations.
Intervention 1: Control; no caffeine intake Intervention 2: Caffeine low dose (2.5 mg/kg of BW) Intervention 3: Caffeine high dose (5 mg/kg of BW)</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Beta-hydroxybutyrate Concentrations</title>
          <description>Plasma beta-hydroxybutyrate (µmol/L) measured over a 4 hour period.</description>
          <units>µmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CTL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.69" spread="12.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caffeine low dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.57" spread="16.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caffeine high dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.99" spread="16.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Glucose Concentrations</title>
        <description>Plasma glucose (mmol/L) measured over a 4 hour period.</description>
        <time_frame>4 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketonemia Following Caffeine Intake</title>
            <description>Participants have to follow three sequential visits of four hours each, which included a breakfast with one of the doses (2.5 or 5 mg/kg) of the caffeine supplement or without any supplement (baseline) and repeated blood sampling in order to evaluate ketone concentrations.
Intervention 1: Control; no caffeine intake Intervention 2: Caffeine low dose (2.5 mg/kg of BW) Intervention 3: Caffeine high dose (5 mg/kg of BW)</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Glucose Concentrations</title>
          <description>Plasma glucose (mmol/L) measured over a 4 hour period.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CTL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.95" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caffeine low dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.96" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caffeine high dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.98" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Cholesterol Concentrations</title>
        <description>Plasma cholesterol (mmol/L) measured over a 4 hour period.</description>
        <time_frame>4 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketonemia Following Caffeine Intake</title>
            <description>Participants have to follow three sequential visits of four hours each, which included a breakfast with one of the doses (2.5 or 5 mg/kg) of the caffeine supplement or without any supplement (baseline) and repeated blood sampling in order to evaluate ketone concentrations.
Intervention 1: Control; no caffeine intake Intervention 2: Caffeine low dose (2.5 mg/kg of BW) Intervention 3: Caffeine high dose (5 mg/kg of BW)</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Cholesterol Concentrations</title>
          <description>Plasma cholesterol (mmol/L) measured over a 4 hour period.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CTL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.26" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caffeine low dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.76" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caffeine high dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.81" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Triglyceride Concentrations</title>
        <description>Plasma triglycerides (mmol/L) measured over a 4 hour period.</description>
        <time_frame>4 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketonemia Following Caffeine Intake</title>
            <description>Participants have to follow three sequential visits of four hours each, which included a breakfast with one of the doses (2.5 or 5 mg/kg) of the caffeine supplement or without any supplement (baseline) and repeated blood sampling in order to evaluate ketone concentrations.
Intervention 1: Control; no caffeine intake Intervention 2: Caffeine low dose (2.5 mg/kg of BW) Intervention 3: Caffeine high dose (5 mg/kg of BW)</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Triglyceride Concentrations</title>
          <description>Plasma triglycerides (mmol/L) measured over a 4 hour period.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CTL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caffeine low dosee</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caffeine high dosee</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 visits of 4 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ketonemia Following Caffeine Intake</title>
          <description>Participants have to follow three sequential visits of four hours each, which included a breakfast with one of the doses (2.5 or 5 mg/kg) of the caffeine supplement or without any supplement (baseline) and repeated blood sampling in order to evaluate ketone concentrations.
Intervention 1: Control; no caffeine intake Intervention 2: Caffeine low dose (2.5 mg/kg of BW) Intervention 3: Caffeine high dose (5 mg/kg of BW)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pr. Stephen Cunnane</name_or_title>
      <organization>Université de Sherbrooke</organization>
      <phone>819-780-2220 ext 45670</phone>
      <email>stephen.cunnane@usherbrooke.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

